Shih YCT, et al. - In this investigation, researchers evaluated the potential value of second-generation BCR-ABL1 tyrosine kinase inhibitors (TKIs) used as frontline therapy in chronic myeloid leukaemia patients in chronic phase with respect to the likelihood of achieving sustained deep molecular responses compared to generic imatinib and the associated cost of each modality. To consider the value of different TKI approaches from the payer's perspective, a decision analytic model was used. The annual price of second-generation TKIs should not exceed $10,000 per year of therapy under the same conditions in developing nations, with a price of generic imatinib of $2100 per year and a willingness to pay of $50,000 per QALY. According to findings, second-generation TKIs at current prices did not offer good value as frontline therapy in chronic myeloid leukaemia in order to obtain sustained deep molecular response and treatment-free remission considering the current prices of second-generation TKIs and of generic imatinib under different pricing scenarios in the USA, Europe, and developing countries.